Alcon announced the US commercial availability of Tryptyr (acoltremon ophthalmic solution) 0.003% for the treatment of the signs and symptoms of dry eye disease (DED). Approved by the FDA in May, eyecare professionals (ECPs) across the United States can now officially begin prescribing Tryptyr to their patients.

Additionally, Alcon announced the launch of an ECP campaign that will focus on the speed of rapid natural tear production with Tryptyr. Specifically, the campaign features ECP tools, including videos and an interactive website, along with a patient website.

Further, the company recently hosted a national broadcast event for ECPs featuring conversations surrounding this DED treatment option.